News
-
Merck Announces Positive Topline Results From the CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia
Enlicitide demonstrated statistically significant and clinically meaningful reductions in LDL-C in both Phase 3 CORALreef HeFH and CORALreef AddOn trials Enlicitide, a novel macrocyclic peptide, has the potential to be the first approved oral PCSK9 inhibitor Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the first two of three Phase 3 clinical trials evaluating the safety and efficacy of enlicitide decanoate, an investigatio
넶5 2025-06-10 -
Biocon is the first generics company to obtain approval for diabetes drug, Liraglutide, in the U.K. - Biocon
This first generic Liraglutide approval in a major regulated market strengthens Biocon’s leadership in complex drug products and future growth drivers for the generics business
넶8 2025-04-23 -
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist - BioSpace
Guangdong, China and Bagsværd, Denmark, 24 March 2025 –The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced that Novo Nordisk and TUL’s wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd. (United Biotechnology), have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and
넶32 2025-03-25
Better Health with ALVANTIS Peptide
Facilities
Contact
Shenzhen Alvantis Pharma Co., Ltd.
Address: Room 1902, Building D3, Nanshan Wisdom Park, No.1001, Xueyuan Avenue, Nanshan District, Shenzhen
E-mail:info@xinspharma.com
Products
